Company intelligence / Profile preview
American Oriental Bioengineering, Inc.
- Ownership
- Private
- Development stage
- Other
Overview
American Oriental Bioengineering has a portfolio of prescription and over-the-counter pharmaceutical products based on both modern drug development and traditional Chinese herbal medicine. Its lead US program AOBO-001 for urinary incontinence entered Phase 1 trials after IND acceptance by the FDA. The company has several approved drugs marketed primarily within China for various indications including urinary issues and respiratory conditions[6]. No recent clinical results are available.
- Therapeutic areas
- Women's HealthImmunologyInfectious DiseasesNephrology
- Modalities
- Primarily small moleculesbotanical/herbal medicines derived from traditional Chinese medicine
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on American Oriental Bioengineering, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on American Oriental Bioengineering, Inc..